Day One Biopharmaceuticals
BiotechUnited States
1
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
3
Indications↗
Distinct diseases across all programs
8
Clinical Trials↗
All sponsored trials (all statuses)
2
Orange Book Patents
Across 1 drug with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
1 drugs in development
Approved1
Phase 31
Phase 21
By Therapeutic Area
top 1
Oncology
1100%
R&D Momentum
30/100
Pipeline Velocity
0/100
Trial Completion Rate
0/100
Pipeline Concentration
100/100
Pipeline Freshness
67/100
Activity
Recent Activity
Earlier
Jun 30, 2026TrialA Phase 1/2, First-in-human, Multicenter Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Mar 19, 2026TrialFIREFLY-301: Tovorafenib in Pediatric LGG
Nov 18, 2024TrialTo Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors
Apr 23, 2024FDAOjemda — OJEMDA
Apr 23, 2024FDAOjemda — OJEMDA
Feb 27, 2023TrialDAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
May 2, 2022TrialTovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors
Details
Company Info
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Regulatory
Regulatory Timeline
20242 events
FDAApr 23
Ojemda — OJEMDA
Application NDA218033 (NDA)
FDAApr 23
Ojemda — OJEMDA
Application NDA217700 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)